HIV multiantigen vaccine - Bavarian Nordic
Alternative Names: 2E8 TCID50 MVA-mBN120B - Bavarian Nordic; MVA-BN HIV multiantigen; MVA-HIV multiantigen vaccine MVA-mBN120B - Bavarian Nordic; MVA-mBN120BLatest Information Update: 29 Sep 2015
At a glance
- Originator Bavarian Nordic
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - HIV-1 infections
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 29 May 2008 Phase-I/II clinical trials in HIV-1 infections in USA (SC)
- 29 Apr 2008 Preclinical trials in HIV-1 infections in USA (Parenteral)
- 29 Apr 2008 Bavarian Nordic files an IND application with the USA FDA to begin a phase I/II trial for treatment of HIV-1 infections